Recombinant Human TNFRSF13B/CD267 protein (rFc Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg1638
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human TNFRSF13B protein Ser2-Thr166 (Accession# O14836-1) with a rabbit IgG Fc tag at the C-terminus. |
| GeneID | 23495 |
| Accession | O14836-1 |
| PredictedSize | 44.8 kDa |
| SDS-PAGE | 32-38 kDa and 44-55 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
TNFRSF13B encodes the transmembrane activator and CAML interactor (TACI) receptor, which drives plasma cell differentiation.TACI is the receptor for the B cell–activating factor (BAFF) and a proliferation-induced ligand (APRIL). TNFRSF13B is expressed as long (L) or short (S) isoforms generated by alternative splicing of exon 2, typically after B cell activation. TNFRSF13B-S lacks the cysteine rich domain 1 needed for binding ligands but retains ability to for receptor trimers and to signal. Indeed, TNFRSF13B complexes containing both -S and -L isoforms may exhibit greater sensitivity to agonists than complexes consisting of only L isoform.
References:
1. Cascalho, Marilia, et al. (2023) Hum Immunol.84(1):27-33. 2. Platt, Jeffrey L et al. (2021) JCI Insight.6(14):e148208. 3. de Mattos Barbosa, Mayara Garcia et al. (2021) JCI Insight.6(17):e150483.